How an unconventional bet - and government funding - could bring a jab to market in record time
The Boston-based biotech eschewed a traditional approach to vaccine development, instead pitching its use of mRNA technology to investors. That pitch paid off this year as the company stands to be one of the first to bring a Covid-19 vaccine to market. Hannah Kuchler, the FT’s US pharma and biotech correspondent, reports on Moderna’s race to find an immunisation for the novel coronavirus.
The FT is making key coronavirus coverage free to read for everyone. Go to ft.com/coronavirusfree to read the latest.
Review clips: Yahoo Finance, CNBC
See acast.com/privacy for privacy and opt-out information.
A transcript for this podcast is currently unavailable, view our accessibility guide.
Get alerts on Behind the Money when a new story is published